Pamidronate
- Atc Codes:M05BA03
- CAS Codes:109552-15-0#57248-88-1
- PHARMGKB ID:109552-15-0#57248-88-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Aredia; Belgium: Aredia, Pamidrin, Pamidronaat, Pamidronate; Bulgaria: Aredia, Pamitor; Cyprus: Aredia; Czech Republic: Aredia, Pamidronát, Pamidronate, Pamitor; Denmark: Aredia, Pamidronatdinatrium; France: Aredia, Ostepam, Pamidronateami, Paminject; Germany: Aredia, Axidronat, Novapam, Pamidron, Pamidronat, P fos, Ribodronat; Greece: Aredia, Pamerit, Pamidronate, Pamidrone; Hungary: Aredia, Pamidronate, Pamifos, Pamitor; Ireland: Aredia; Italy: Aredia, Pamidronato, Texpami; Lithuania: Pamidronate, Pamitor; Luxembourg: Aredia, Pamidronat; Poland: Aredia, Pamidia, Pamidronat, Pamistad, Pamitor; Portugal: Pamidran, Pamidronato; Romania: Aredia, Pamidronat, Pamired; Slovakia: Aredia, Pamidronate, Pamifos, Pamitor; Slovenia: Aredia, Pamitor; Spain: Aredia, Pamidronato, Pamifos; Sweden: Pramidrocell, Pamidronat, Pamidronatdinatrium; UK: Aredia, Pamidronate.
North America
Canada: Aredia, Pamidronate; USA: Aredia, Pamidronate.
Latin America
Argentina: Aminomux, Pamdosa, Pamidronato, Pandrat; Brazil: Aredia, Pamidrom, Pamidronato; Mexico: Aredia.
Asia
Japan: Aredia, Pamidronate.
Drug combinations
Chemistry
Pamidronate Disodium: C~3~H~9~NNa~2~O~7~P~2~ 5H~2~O. Mw: 369.11. (1) Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt, pentahydrate; (2) Disodium dihydrogen (3-amino-1-hydroxypropylidene)diphosphonate, pentahydrate. CAS-109552-15-0; CAS-57248-88-1 (anhydrous)(1990).
Pharmacologic Category
Bone Resorption Inhibitors. Antidote. Bisphosphonate Derivative. (ATC-Code: M05BA03).
Mechanism of action
Inhibits bone resorption via actions on osteoclasts or on osteoclast precursors.
Therapeutic use
Treatment of hypercalcemia associated with malignancy. Treatment of osteolytic bone lesions associated with multiple myeloma or metastatic breast cancer. Moderate to severe Paget’s disease of bone.
Pregnancy and lactiation implications
Crosses placenta and causes nonteratogenic embryo/fetal effects in animals. Should not be used in pregnancy. Theoretically, there may be risk of fetal harm when pregnancy follows completion of therapy. Excretion in breast milk unknown (use caution).
Unlabeled use
Treatment of pediatric osteoporosis, treatment of osteogenesis imperfecta.
Contraindications
Hypersensitivity to pamidronate, other bisphosphonates, or any component of the formulation.
Warnings and precautions
Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain reported. Electrolyte abnormalities (including hypophosphatemia, hypokalemia, hypomagnesemia, and hypocalcemia) might occur. Rare cases of symptomatic hypocalcemia, including tetany reported. Oral therapy associated with leukopenia. Associated with osteonecrosis, primarily of jaw, observed mostly in cancer patients, but also in postmenopausal osteoporosis and other diagnoses. Invasive dental procedures should be avoided during treatment. Initial or single doses associated with renal deterioration, progressing to renal failure and dialysis. Glomerulosclerosis (focal segmental) with or without nephrotic syndrome also reported. Vein irritation and thrombophlebitis may occur with infusions. Use caution with history of thyroid surgery. For treatment of bone metastases, use not recommended in severe renal impairment.